Skip to main content
SpringerLink
Log in

Dyslipidemia in Diabetes Mellitus and Chronic Kidney Disease

  • Chapter
  • First Online:
Diabetes and Kidney Disease

  • 1935 Accesses

Abstract

This chapter discusses dyslipidemia in patients with both Type 2 diabetes mellitus and chronic kidney disease. We highlight similarities and differences in the pathophysiology of diabetic dyslipidemia and dyslipidemia of chronic kidney disease and outline the typical lipid profile in patients with both conditions. We also discuss the impact of coexisting diabetes and chronic kidney disease on cardiovascular risk. A comprehensive review of the literature for the evidence behind the therapeutic targets and various treatment modalities is provided with emphasis on both benefits and shortcomings as well as applications to specific population groups such as patients on dialysis or post-transplant.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. US renal data system 2010 annual data report. Am J Kidney Dis. 2011;57(1 Suppl 1):A8, e1–526. http://www.ncbi.nlm.nih.gov/pubmed/21184928. Accessed 31 Oct 2013

  2. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–154. http://www.ncbi.nlm.nih.gov/pubmed/17276798. Accessed 12 Oct 2013.

  3. Cooper ME, Jandeleit-Dahm K, Thomas MC. Targets to retard the progression of diabetic nephropathy. Kidney Int. 2005;68(4):1439–45. http://www.ncbi.nlm.nih.gov/pubmed/16164619. Accessed 12 Oct 2013.

  4. Olyaei A, Steffl JL, Maclaughlan J, Trabolsi M, Quadri SP, Abbasi I, et al. HMG-CoA Reductase Inhibitors in Chronic Kidney Disease. Am J Cardiovasc Drugs. 2013;13(6):385–98. http://www.ncbi.nlm.nih.gov/pubmed/23975627. Accessed 31 Oct 2013.

  5. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39. http://www.ncbi.nlm.nih.gov/pubmed/18061058. Accessed 26 Nov 2013.

  6. Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011;31(1–3):189–96. http://www.ncbi.nlm.nih.gov/pubmed/21228589. Accessed 23 Jul 2013.

  7. Moin DS, Rohatgi A. Clinical applications of advanced lipoprotein testing in diabetes mellitus. Clin Lipidol. 2011;6(4):371–87.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int. 1996;49(5):1360–71. http://www.ncbi.nlm.nih.gov/pubmed/8731101. Accessed 12 Oct 2013.

  9. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78(5):1287–95. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=423815&tool=pmcentrez&rendertype=abstract. Accessed 16 Nov 2013.

  10. Ooi EMM, Chan DT, Watts GF, Chan DC, Ng TWK, Dogra GK, et al. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. J Lipid Res. 2011;52(4):794–800. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3284168&tool=pmcentrez&rendertype=abstract. Accessed 16 Nov 2013.

  11. Vaziri ND, Yuan J, Ni Z, Nicholas SB, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol. 2012;16(2):238–43. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3417131&tool=pmcentrez&rendertype=abstract. Accessed 12 Oct 2013.

  12. Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int. 1990;37(3):854–8. http://www.ncbi.nlm.nih.gov/pubmed/2313975. Accessed 16 Nov 2013.

  13. Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol. 1997;273(6 Pt 2):F925–30. http://www.ncbi.nlm.nih.gov/pubmed/9435681. Accessed 16 Nov 2013.

  14. Hagström E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33–9. http://www.ncbi.nlm.nih.gov/pubmed/16793947. Accessed 16 Nov 2013.

  15. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant. 1998;13(11):2833–41. http://www.ncbi.nlm.nih.gov/pubmed/9829487. Accessed 1 Nov 2013.

  16. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol. 2012;60(23):2372–9. http://www.ncbi.nlm.nih.gov/pubmed/23141484. Accessed 12 Oct 2013.

  17. Farbakhsh K, Kasiske BL. Dyslipidemias in patients who have chronic kidney disease. Med Clin North Am. 2005;89:689–99.

    Article  PubMed  Google Scholar 

  18. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol. 2008;28(6):958–73. http://www.ncbi.nlm.nih.gov/pubmed/18612199. Accessed 16 Nov 2013.

  19. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant. 1998;13(9):2281–7. http://www.ncbi.nlm.nih.gov/pubmed/9761510. Accessed 16 Nov 2013.

  20. Chu M, Wang AYM, Chan IHS, Chui SH, Lam CWK. Serum small-dense LDL abnormalities in chronic renal disease patients. Br J Biomed Sci. 2012;69(3):99–102. http://www.ncbi.nlm.nih.gov/pubmed/23057155. Accessed 16 Nov 2013.

  21. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest. 1996;97(10):2167–73. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=507295&tool=pmcentrez&rendertype=abstract. Accessed 1 Nov 2013.

  22. Bairaktari E, Elisaf M, Tsolas O, Siamopoulos KC. Serum Lp(a) levels in patients with moderate renal failure. Nephron 1998;79(3):367–8. http://www.ncbi.nlm.nih.gov/pubmed/9678450. Accessed 1 Nov 2013.

  23. Haffner SM, Gruber KK, Aldrete G, Morales PA, Stern MP, Tuttle KR. Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol. 1992;3(5):1156–62. http://www.ncbi.nlm.nih.gov/pubmed/1482754. Accessed 1 Nov 2013.

  24. Mattock M, Cronin N, Cavallo-Perin P, Idzior-Walus B, Penno G, Bandinelli S, et al. Plasma lipids and urinary albumin excretion rate in type 1 diabetes mellitus: The EURODIAB IDDM Complications Study. Diabet Med. 2001;18:59–67. http://discovery.ucl.ac.uk/26964/

  25. Joven J, Villabona C, Vilella E, Masana L, Albertí R, Vallés M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med. 1990;323(9):579–84. http://www.ncbi.nlm.nih.gov/pubmed/2381443. Accessed 12 Oct 2013.

  26. Han S, Vaziri ND, Gollapudi P, Kwok V, Moradi H. Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome. Am J Transl Res. 2013;5:246–53. http://www.ncbi.nlm.nih.gov/pubmed/23573368

  27. Johansson AC, Samuelsson O, Attman PO, Haraldsson B, Moberly J, Knight-Gibson C, et al. Dyslipidemia in peritoneal dialysis—relation to dialytic variables. Perit Dial Int. 2000;20(3):306–14. http://www.ncbi.nlm.nih.gov/pubmed/10898048. Accessed 12 Oct 2013.

  28. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M. Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int. 1990;37(3):980–90. http://www.ncbi.nlm.nih.gov/pubmed/2313985. Accessed 12 Oct 2013.

  29. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int Suppl. 1997;62:S48–52. http://www.ncbi.nlm.nih.gov/pubmed/9350680. Accessed 12 Oct 2013.

  30. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992;61(4):377–82. http://www.ncbi.nlm.nih.gov/pubmed/1501732. Accessed 12 Oct 2013.

  31. Mak RH. Insulin secretion in uremia: effect of parathyroid hormone and vitamin D metabolites. Kidney Int Suppl. 1989;27:S227–30. http://www.ncbi.nlm.nih.gov/pubmed/2699996. Accessed 12 Oct 2013.

  32. Ginsberg HN, Zhang Y-L, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring). 2006;14 Suppl 1:41S–49S. http://www.ncbi.nlm.nih.gov/pubmed/16642962. Accessed 12 Oct 2013.

  33. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–421. http://www.ncbi.nlm.nih.gov/pubmed/12485966. Accessed 19 Sep 2013.

  34. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987;30(3):123–31. http://www.ncbi.nlm.nih.gov/pubmed/3556287. Accessed 16 Sep 2013.

  35. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012;380(9844):807–14. http://www.ncbi.nlm.nih.gov/pubmed/22717317. Accessed 10 Oct 2013.

  36. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56(6):2214–9. http://www.ncbi.nlm.nih.gov/pubmed/10594797. Accessed 13 Oct 2013.

  37. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002;61(4):1486–94. http://www.ncbi.nlm.nih.gov/pubmed/11918756. Accessed 13 Oct 2013.

  38. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–69. http://www.ncbi.nlm.nih.gov/pubmed/14581387. Accessed 25 Sep 2013.

  39. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13(3):745–53. http://www.ncbi.nlm.nih.gov/pubmed/11856780. Accessed 13 Oct 2013.

  40. Hallan S, Astor B, Romundstad S, Aasarød K, Kvenild K, Coresh J. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med. 2007;167(22):2490–6. http://www.ncbi.nlm.nih.gov/pubmed/18071172. Accessed 13 Oct 2013.

  41. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375(9731):2073–81. http://www.ncbi.nlm.nih.gov/pubmed/20483451. Accessed 1 Oct 2013.

  42. Mann JFE, Gerstein HC, Dulau-Florea I, Lonn E. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int Suppl. 2003;(84):S192–6. http://www.ncbi.nlm.nih.gov/pubmed/12694342. Accessed 13 Oct 2013.

  43. Rashidi A, Sehgal AR, Rahman M, O’Connor AS. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol. 2008;102(12):1668–73. http://www.ncbi.nlm.nih.gov/pubmed/19064021. Accessed 13 Oct 2013.

  44. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279(8):585–92. http://www.ncbi.nlm.nih.gov/pubmed/9486752. Accessed 13 Oct 2013.

  45. Shepherd J, Kastelein JJP, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448–54. http://www.ncbi.nlm.nih.gov/pubmed/18402899

  46. Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med. 2011;154(5):310–8. http://www.ncbi.nlm.nih.gov/pubmed/21357908. Accessed 13 Oct 2013.

  47. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266. http://www.ncbi.nlm.nih.gov/pubmed/11904577. Accessed 21 Sep 2013.

  48. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110(5):588–636. http://www.ncbi.nlm.nih.gov/pubmed/15289388. Accessed 20 Sep 2013.

  49. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629–36. http://www.ncbi.nlm.nih.gov/pubmed/11304102. Accessed 16 Oct 2013.

  50. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau J-L, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95. http://www.ncbi.nlm.nih.gov/pubmed/15385655. Accessed 16 Oct 2013.

  51. Chang Y-T, Wu J-L, Hsu C-C, Wang J-D, Sung J-M. Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: a nation-wide follow-up study during 1998-2009. Diabetes Care 2014;37(1):277–85. http://www.ncbi.nlm.nih.gov/pubmed/23920086. Accessed 22 Oct 2013.

  52. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267–78. http://www.ncbi.nlm.nih.gov/pubmed/16214597. Accessed 27 Sep 2013.

  53. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(21):2307–13. http://www.ncbi.nlm.nih.gov/pubmed/17130382. Accessed 2 Oct 2013.

  54. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58. http://www.ncbi.nlm.nih.gov/pubmed/12686036. Accessed 2 Oct 2013.

  55. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54(5):810–9. http://www.ncbi.nlm.nih.gov/pubmed/19540640. Accessed 19 Oct 2013.

  56. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361(9374):2005–16. http://www.ncbi.nlm.nih.gov/pubmed/12814710. Accessed 19 Oct 2013.

  57. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728–34. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1770346&tool=pmcentrez&rendertype=abstract. Accessed 19 Oct 2013.

  58. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005;112(2):171–8. http://www.ncbi.nlm.nih.gov/pubmed/15998677. Accessed 19 Oct 2013.

  59. Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008;83(8):870–9. http://www.ncbi.nlm.nih.gov/pubmed/18674471. Accessed 19 Oct 2013.

  60. Shepherd J, Kastelein JJP, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131–9. http://www.ncbi.nlm.nih.gov/pubmed/17942759. Accessed 19 Oct 2013.

  61. Sukhija R, Bursac Z, Kakar P, Fink L, Fort C, Satwani S, et al. Effect of statins on the development of renal dysfunction. Am J Cardiol. 2008;101(7):975–9. http://www.ncbi.nlm.nih.gov/pubmed/18359317. Accessed 19 Oct 2013.

  62. Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52(3):412–24. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2897819&tool=pmcentrez&rendertype=abstract. Accessed 19 Oct 2013.

  63. Strippoli GFM, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336(7645):645–51. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2270960&tool=pmcentrez&rendertype=abstract. Accessed 19 Oct 2013.

  64. Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16(12):3748–54. http://www.ncbi.nlm.nih.gov/pubmed/16251235. Accessed 19 Oct 2013.

  65. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis. 2007;49(3):373–82. http://www.ncbi.nlm.nih.gov/pubmed/17336698. Accessed 19 Oct 2013.

  66. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3(3):271–9. http://dx.doi.org/10.1038/kisup.2013.34. Accessed 1 Dec 2013.

  67. Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis. 2012;60(5):747–69. http://www.ncbi.nlm.nih.gov/pubmed/22999165. Accessed 28 May 2013.

  68. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51(25):2375–84. http://www.ncbi.nlm.nih.gov/pubmed/18565393. Accessed 25 Oct 2013.

  69. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60(1):350–7. http://www.ncbi.nlm.nih.gov/pubmed/11422771. Accessed 25 Oct 2013.

  70. Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol. 2003;14(10):2556–72. http://www.ncbi.nlm.nih.gov/pubmed/14514733. Accessed 25 Oct 2013.

  71. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. 2003;41(5 Suppl):11–7. http://www.ncbi.nlm.nih.gov/pubmed/12776309. Accessed 26 Oct 2013.

  72. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356(9224):147–52. http://www.ncbi.nlm.nih.gov/pubmed/10963260. Accessed 26 Oct 2013.

  73. Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48. http://www.ncbi.nlm.nih.gov/pubmed/16034009

  74. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61(1):297–304. http://www.ncbi.nlm.nih.gov/pubmed/11786112. Accessed 26 Oct 2013.

  75. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2005;45(1):119–26. http://www.ncbi.nlm.nih.gov/pubmed/15696451. Accessed 26 Oct 2013.

  76. Fellström B, Holdaas H, Jardine AG, Rose H, Schmieder R, Wilpshaar W, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res. 2007;30(5):314–22. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2790755&tool=pmcentrez&rendertype=abstract. Accessed 26 Oct 2013.

  77. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377(9784):2181–92. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3145073&tool=pmcentrez&rendertype=abstract. Accessed 26 Oct 2013.

  78. Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, et al. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011;22(7):1335–41. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3137581&tool=pmcentrez&rendertype=abstract. Accessed 26 Oct 2013.

  79. Svensson M, Schmidt EB, Jørgensen KA, Christensen JH. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol. 2006;1(4):780–6. http://www.ncbi.nlm.nih.gov/pubmed/17699287. Accessed 26 Oct 2013.

  80. Jardine A. Assessing cardiovascular risk profile of immunosuppressive agents. Transplantation 2001;72(12 Suppl):S81–8. http://www.ncbi.nlm.nih.gov/pubmed/11833146. Accessed 29 Oct 2013.

  81. Jardine A, Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J Clin Pharm Ther. 1999;24(6):397–408. http://www.ncbi.nlm.nih.gov/pubmed/10651972. Accessed 29 Oct 2013.

  82. Jardine AG, Holdaas H, Fellström B, Cole E, Nyberg G, Grönhagen-Riska C, et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant. 2004;4(6):988–95. http://www.ncbi.nlm.nih.gov/pubmed/15147434. Accessed 29 Oct 2013.

  83. Davis TME, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54(2):280–90. http://www.ncbi.nlm.nih.gov/pubmed/21052978. Accessed 29 Oct 2013.

  84. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2879499&tool=pmcentrez&rendertype=abstract. Accessed 17 Oct 2013.

  85. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849–61. http://www.ncbi.nlm.nih.gov/pubmed/16310551. Accessed 24 Oct 2013.

  86. Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 2005;46(5):1086–92. http://www.ncbi.nlm.nih.gov/pubmed/16230515. Accessed 29 Oct 2013.

  87. Anami Y, Kobori S, Sakai M, Kasho M, Nishikawa T, Yano T, et al. Human beta-migrating very low density lipoprotein induces foam cell formation in human mesangial cells. Atherosclerosis. 1997;135(2):225–34. http://www.ncbi.nlm.nih.gov/pubmed/9430372. Accessed 29 Oct 2013.

  88. Olufadi R, Byrne CD. Effects of VLDL and remnant particles on platelets. Pathophysiol Haemost Thromb. 2006;35(3-4):281–91. http://www.ncbi.nlm.nih.gov/pubmed/16877877. Accessed 29 Oct 2013.

  89. Shen GX. Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells. Mol Cell Biochem. 2003;246(1–2):69–74. http://www.ncbi.nlm.nih.gov/pubmed/12841345. Accessed 29 Oct 2013.

  90. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58(1):293–301. http://www.ncbi.nlm.nih.gov/pubmed/10886574. Accessed 29 Oct 2013.

  91. Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, et al. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008;31(10):2006–12. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2551645&tool=pmcentrez&rendertype=abstract. Accessed 18 Oct 2013.

  92. Mora S. Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. Circulation 2009;119(17):2396–404. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2735461&tool=pmcentrez&rendertype=abstract. Accessed 29 Oct 2013.

  93. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard B V, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15):1512–24. http://www.ncbi.nlm.nih.gov/pubmed/18402913. Accessed 27 May 2013.

  94. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823–8. http://www.ncbi.nlm.nih.gov/pubmed/3773199. Accessed 29 Oct 2013.

  95. Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J. 1983;106(5 Pt 2):1191–200. http://www.ncbi.nlm.nih.gov/pubmed/6637784. Accessed 29 Oct 2013.

  96. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88(4 Pt 1):1421–30. http://www.ncbi.nlm.nih.gov/pubmed/8403288. Accessed 29 Oct 2013.

  97. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85(1):37–45. http://www.ncbi.nlm.nih.gov/pubmed/1728471. Accessed 29 Oct 2013.

  98. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013. http://www.ncbi.nlm.nih.gov/pubmed/24222016. Accessed 13 Nov 2013.

  99. Farbakhsh K, Kasiske BL. Dyslipidemias in patients who have chronic kidney disease. Med Clin North Am. 2005;89(3):689–99. http://www.ncbi.nlm.nih.gov/pubmed/15755473. Accessed 29 Oct 2013.

  100. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(4):S1–77.

    Google Scholar 

  101. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2012;302(6):H1219–30. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3311482&tool=pmcentrez&rendertype=abstract. Accessed 31 Oct 2013.

  102. Nickenig G, Sachinidis A, Michaelsen F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997;95(2):473–8. http://www.ncbi.nlm.nih.gov/pubmed/9008466. Accessed 31 Oct 2013.

  103. Li D, Saldeen T, Romeo F, Mehta JL. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 2000;102(16):1970–6. http://www.ncbi.nlm.nih.gov/pubmed/11034947. Accessed 31 Oct 2013.

  104. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol. 2007;6:12. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1853076&tool=pmcentrez&rendertype=abstract. Accessed 31 Oct 2013.

  105. Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther. 2012;29(9):736–46. http://www.ncbi.nlm.nih.gov/pubmed/22923161. Accessed 31 Oct 2013.

  106. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993;16(10):1387–90. http://www.ncbi.nlm.nih.gov/pubmed/8269798. Accessed 31 Oct 2013.

  107. Fitch K, Abbara S, Lee H, Stavrou E, Sacks R, Michel T, et al. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS. 2012;26(5):587–97. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3675446&tool=pmcentrez&rendertype=abstract. Accessed 12 Oct 2013.

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, Endocrinology and Metabolism, Advocate Christ Medical Center, 4440 West 95th Street, Oak Lawn, IL, 60453, USA

    Armand Krikorian M.D., F.A.C.E.

  2. Internal Medicine, Endocrinology and Metabolic Diseases, Saint Vincent Charity Medical Center, Cleveland, OH, USA

    Joumana T. Chaiban M.D.

  3. Case Western Reserve University, Cleveland, OH, USA

    Joumana T. Chaiban M.D.

Authors
  1. Armand Krikorian M.D., F.A.C.E.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joumana T. Chaiban M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Armand Krikorian M.D., F.A.C.E. .

Editor information

Editors and Affiliations

  1. University of Illinois, Chicago, Illinois, USA

    Edgar V. Lerma

  2. Nephrology Section, Tulane University Medical School, New Orleans, Louisiana, USA

    Vecihi Batuman

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Krikorian, A., Chaiban, J.T. (2014). Dyslipidemia in Diabetes Mellitus and Chronic Kidney Disease. In: Lerma, E., Batuman, V. (eds) Diabetes and Kidney Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0793-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0793-9_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0792-2

  • Online ISBN: 978-1-4939-0793-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation